Insmed Incorporated (INSM) Enters 2026 With Momentum

Insmed Incorporated (NASDAQ:INSM) is among the 10 Unstoppable Stocks to Buy and Hold for the Next 3 Years.

Insmed Incorporated (NASDAQ:INSM) is one of the Unstoppable Stocks to Buy and Hold for the Next 3 Years. On February 19, the company released its Q4 2025 and FY 2025 results, with the company highlighting that its US commercial launch of BRINSUPRI has exceeded its expectations. Insmed Incorporated (NASDAQ:INSM) expects FY 2026 BRINSUPRI revenues of at least $1 billion. The company is evaluating the potential effect of evolving US policies, which can impact the timing for future potential international commercial launches.

Insmed Incorporated (NASDAQ:INSM) entered 2026 with momentum, which places the company for leadership across both bronchiectasis and NTM. Over the upcoming year, the company plans to accelerate and expand the US launch of BRINSUPRI. It also plans to grow ARIKAYCE. The company expects FY 2026 ARIKAYCE revenues of between $450 million and $470 million.

It expects that the total of its pre-clinical research programs would make up less than 20% of the overall expenditures.

Insmed Incorporated (NASDAQ:INSM) is a biopharmaceutical company that develops and commercializes therapies for patients with serious and rare diseases.

We recently covered that Insmed (INSM) is poised for 2026 upside, you can read that update here.

While we acknowledge the potential of INSM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best FMCG Stocks to Invest In According to Analysts and 11 High-Flying Stocks to Buy Right Now.

Disclosure: None. Follow Insider Monkey on Google News.